Camilla Soenderby Email and Phone Number
Camilla Soenderby work email
- Valid
Camilla Soenderby personal email
- Valid
Seasoned C-Suite, Board Director and Senior Advisor with 20 years of international leadership experience in biopharma. Held senior operational and strategic roles spanning C-level, global, regional, and country level for top 10 players in EU, US and Asia. Large international P&L management and operational experience. Extensive global portfolio commercialization experience leading global multidisciplinary teams to drive portfolio strategy, global product commercialization, launch and life cycle management across rare diseases, oncology and specialty condition. Worked in close partnership with clinical development, regulatory/medical affairs, RWE and HEOR. Experienced in co-chairing the portfolio review committee with the Head of R&D to drive informed R&D and product-related decisions. Skilled in business transformation, M&A and integration of biotech businesses. Broad governance experience from NED roles and various corporate and industry committees. Senior advisor experience from Novo Holdings and EQT Partners. Began career as a McKinsey management consultant focused on healthcare.Executive Experience* Corporate Officer, Chief Patient Value & Product Strategy Officer, Takeda* Senior Vice President, Head of Global Product Strategy, Shire* Region Head, Roche Pharmaceuticals (South, East and Central Europe)* General Manager, Abbott Laboratories, United Kingdom (Now AbbVie)* General Manager, Abbott Laboratories, Sweden (Now AbbVie)* Turnaround Project Manager for Schering-Plough, China* General Manager, Schering-Plough, Taiwan* Senior Strategic Management Associate, Schering-Plough’s regional HQ, Singapore* Management Consultant at McKinsey & Company focused on biopharma, medical devices & diagnostics* Royal Danish Embassy, Commercial Assistant, ChinaSenior Advisor experience* Novo Holdings: Member of Novo Advisory Group* EQT partners: Industrial Advisor, Healthcare industry (Private equity)Board Experience* BB Biotech (investment company, Listed SIX Swiss Exchange/Frankfurt Stock Exchange): Board Director & Audit Committee Member* Abivax (late stage clinical-stage biotech company, listed NASDAQ/Euronext Paris): Board Director & Appointment and Compensation Committee member* Affibody (clinical-stage biopharma company): Board Director* F2G (clinical-stage biotech company): Board Director and Board ESG Representative* Takeda Pharmaceuticals International AG: Board Director* Abbott: Board Director for 20 private holding and subsidiary companies in the UK for AbbVie, Abbott Laboratories, Abbott Vascular and KNOLL
Bb Biotech
View- Website:
- bbbiotech.com
- Employees:
- 17
-
Board Director | Member Of Audit CommitteeBb BiotechCanton Of Zug, Switzerland
-
Member Board Of Directors & Audit CommitteeBb Biotech 2024 - PresentChBB Biotech invests in biotechnology companies and is one of the world’s largest investors in this sector. Listed on SIX Swiss Exchange and Frankfurt Stock Exchange
-
Member Board Of Directors & Appointments And Compensation CommitteeAbivax 2024 - PresentParis, Île-De-France, FrAbivax is a late-stage biotechnology company focused on developing innovative therapeutics for chronic inflammatory diseases - listed on NASDAQ and EURONEXT. -
Novo Holding Advisory Group, MemberNovo Holdings 2022 - PresentHellerup, Gentofte, DkThe Novo Advisory Group is an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its larger life science investments. Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes, and invests and manages the assets of the Novo Nordisk Foundation (≈ USD 106 Bn total assets in 2021) -
Member Board Of DirectorsAffibody Ab 2021 - PresentHaga, Stockholm, SeA clinical stage biopharma company focused on developing bi- and multi-specific antibody mimetics targeting autoimmune diseases and targeted radioimmunotherapy. A Patricia Industries holding, part of Investor AB. -
Member Board Of Directors & Board Esg RepresentativeF2G 2021 - PresentManchester, England, GbA clinical stage biopharma company focused on developing therapies for rare life-threatening invasive fungal diseases. Venture capital syndicate-backed company. -
Industrial Advisor, Healthcare IndustryEqt Partners/Eqt Ab 2020 - PresentStockholm, Stockholm, SeProvide due diligence assessment and advice for potential acquisitions in EU and US.(EQT is a leading private equity group with app. EUR 71 Bn in assets under management) -
Corporate Officer, Patient Value & Product StrategyTakeda Jan 2019 - Oct 2020Tokyo, JpMember of the Takeda Executive Team, the Business Review Committee and the Risk, Ethics & Compliance Committee. Co-chair of the Portfolio Review Committee. Led the establishment of a global function (following the acquisition of Shire) that comprised Global Commercial Strategy, Global Market Access & Pricing, Global Commercial Excellence, and Global Patient Advocacy. Led a portfolio of global brands with > US$13 Bn in sales and launch preparation a for large clinical pipeline with cross functional teams based in Boston and Zurich. Worked in close partnership with R&D, Medical & Regulatory Affairs, Investor Relations, Supply and the Regions. Executive sponsor for cross company initiative to accelerate diagnosis of rare diseases using digital technology incl. AI. -
Svp, Head Of Global Product StrategyShire 2018 - 2019Tokyo, Jp, JpReported to the CEO. Chair of The In-line Committee responsible for reviewing Shire's global commercial performance vs Budget (sales & profit for Global / US / Int’l), developing mitigating strategies, approving global financial targets (Budget and LRP for Global / US / Int’l), and overseeing supply from a commercial perspective. Chaired the Executive Committee's Quarterly Business Reviews. Oversaw the development of portfolio and global product strategies for six global therapeutic franchises (rare diseases, oncology, specialty conditions) as well as Global Market Access & Pricing, and Global Commercial Operation (In total 40 marketed brands with > US$ 15 Bn and a pipeline of 10 NMEs and 14 LCM assets). Member of the Pipeline Committee.(Takeda acquired Shire on January 8th, 2019) -
Industrial AdvisorEqt Partners/Eqt Ab 2017 - 2018Stockholm, Stockholm, SeProvided independent due diligence assessment and advice for potential acquisitions in healthcare.
-
Region Head, South, East And Central Europe, Roche PharmaceuticalsRoche Mar 2014 - Dec 2015Switzerland 🇨🇭 , ChLed a region with sales of $US 1.5 billion and app. 1500 people. Managed 11 General Managers (GMs) with full P&L responsibility for Pharma (Switzerland, Austria, Greece, Israel, Portugal, Slovakia, Hungary, Bulgaria, Romania, Slovenia, Croatia) and a dedicated cross functional team (incl. finance, commercial, market access, medical and HR) to support the sub-region. Also a member of the European Leadership Team. -
General ManagerAbbott 2009 - 2013Abbott Park, Illinois, UsLegal & compliance responsibility for Abbott UK (Host GM for 12 diversified health care divisions each led by a GM, total 2000 employees). P&L responsibility for the key division, Proprietary Pharmaceuticals Division (PPD - now called AbbVie), $US 570MM, 400 employees.Appointed Director of the Board of several holding and subsidiary companies for Abbott. -
General ManagerAbbott 2008 - 2009Abbott Park, Illinois, UsLegal & compliance responsibility for Abbott Sweden (Host GM for 5 diversified health care divisions each lead by a GM, total 200 employees). P&L responsibility for the key division, Proprietary Pharmaceuticals Division (PPD - now called AbbVie), $US 96MM,107 employees.
-
Board MemberThe Association Of The British Pharmaceutical Industry (Abpi) 2010 - 2012London, Gb -
Board MemberThe Swedish Association Of The Pharmaceutical Industry, Lif 2008 - 2009Stockholm, Se -
Turnaround Project Manager For Schering-Plough ChinaSchering Pharmaceuticals 2005 - 2007Kenilworth, Nj, UsLed a complex and strategic turnaround project for Schering-Plough (S-P) China to analyse growth opportunities, lay out a strategic plan to accelerate short and long term sales and earnings. Reported to the Group Vice President Asia Pacific. The project had high corporate attention. Provided monthly project progress updates directly to the Executive VP & President of Global Pharmaceutical business in the US. -
General Manager, Schering-Plough TaiwanSchering Pharmaceuticals 2003 - 2005Kenilworth, Nj, UsGained start-up kind of experience from leading Schering-Plough Taiwan that was extremely leanly staffed and with weak processes. Got extensive hands-on experience in driving sales & marketing, market access and public affairs, medical & regulatory affairs, finance, and HR. Had to build cross-cultural trust fast as only foreigner among Taiwanese. Prepared for launch of global blockbuster in partnership with MSD.
-
Senior Management Associate, Regional Headquaters Far East And South Africa, Schering PloughSchering Pharmaceuticals 2002 - 2003Kenilworth, Nj, UsReported to the SVP for Far East & South Africa and advised on regions top priorities. Worked closely with the region’s GMs to ensure a steady progress on key priorities. Involved in driving key projects in Australia, South Africa, Taiwan, and Hong Kong
-
Senior Management Consultant, Mckinsey & CompanyMckinsey & Company 1999 - 2002UsSpecialised in growth and business building projects in the biotechnology, pharmaceutical, medical devices and diagnostic industries. -
Commercial Assistant, Royal Danish Embassy, ChinaRoyal Danish Embassy, Beijing 1998 - 1998Assisted Danish companies in working out strategic plans for how to enter and develop the Chinese market through export promotional activities.
Camilla Soenderby Skills
Camilla Soenderby Education Details
-
University Of St.GallenSt. Gallen Board Academy -
Københavns Universitet - University Of Copenhagen
Frequently Asked Questions about Camilla Soenderby
What company does Camilla Soenderby work for?
Camilla Soenderby works for Bb Biotech
What is Camilla Soenderby's role at the current company?
Camilla Soenderby's current role is Board Director | Member of Audit Committee.
What is Camilla Soenderby's email address?
Camilla Soenderby's email address is ca****@****ail.com
What schools did Camilla Soenderby attend?
Camilla Soenderby attended University Of St.gallen, Københavns Universitet - University Of Copenhagen.
What skills is Camilla Soenderby known for?
Camilla Soenderby has skills like Strategy, Pharmaceutical Industry, Business Strategy, Product Launch, Market Access, Business Development, Management, Strategic Planning, P&l Management, Cross Functional Team Leadership, Pharmaceutical Sales, Executive Management.
Who are Camilla Soenderby's colleagues?
Camilla Soenderby's colleagues are Olivia Woolley Meza, Christian Koch.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial